biosimilar



dynaCERT Inc.
Latest Comments
image_pdfimage_print

Valeo Pharma’s Redesca™ rollout is progressing rapidly, proving the value of its business model, as its revenue grows 280% in Q3, 2021

Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF | FSE: VP2) (“Valeo”) is a specialty pharmaceutical marketing company dedicated to […]


Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19

In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: […]